Kadian
Company: Purepac Pharmaceutical
Approval Status: Approved July 1996
Treatment for: chronic pain
Areas: Musculoskeletal; Neurology; Oncology
General Information
Other Useful Resources
Kadian, a single daily dosage sustained-release morphine product, has been approved by the FDA. Kadian provides relief for chronic moderate to severe pain (pain related to cancer), and has been demonstrated to be as effective when taken once a day as conventional morphine products taken every four hours.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
